Coherus Oncology (CHRS) Notes Payables (2013 - 2025)

Coherus Oncology has disclosed Notes Payables across 9 years of filings, most recently posting $26.2 million for Q1 2025.

• In Q1 2025, Notes Payables changed N/A year-over-year to $26.2 million; the TTM figure through Mar 2025 stood at $26.2 million (changed N/A YoY), while the FY2024 annual figure was $13.6 million, changed N/A from the prior year.
• Notes Payables came in at $26.2 million for Q1 2025 at Coherus Oncology, up from $13.6 million in the prior quarter.
• In the past five years, Notes Payables ranged from a high of $81.0 million in Q3 2021 to a low of $90000.0 in Q2 2023.
• Average Notes Payables over 4 years is $33.4 million, with a median of $13.6 million recorded in 2024.
• The largest YoY upside for Notes Payables was 10124.44% in 2024 against a maximum downside of 10124.44% in 2024.
• Over 4 years, Notes Payables stood at $81.0 million in 2021, then plunged by 99.89% to $90000.0 in 2023, then surged by 15033.33% to $13.6 million in 2024, then soared by 92.57% to $26.2 million in 2025.
• Per Business Quant data, the three most recent Notes Payables figures were $26.2 million in Q1 2025, $13.6 million in Q4 2024, and $9.2 million in Q3 2024.